Evidence map›Paper›PMID 42400713›Full record

ArticleScience China. Life sciences2026

Targeting SYK to alleviate MDSC-driven immunosuppression and augment anti-PD1 efficacy.

Zhiyang Zeng, Xiya Cao, Changwei Li, Youyuan He, Haozhe Guo, Xiaoya Cao, Tingyue Gong, Jialiang Sun, Yaqiang Hu, Zhongwei Hu and 14 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Zhiyang Zeng *Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai Academy of Natural Sciences (SANS), Shanghai, 200241, China.
Xiya Cao *Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai Academy of Natural Sciences (SANS), Shanghai, 200241, China.
Changwei Li *Department of Orthopedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopedics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Youyuan HeFengxian Central Hospital Affiliated to Southern Medical University, Shanghai, 201499, China.
Haozhe GuoShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai Academy of Natural Sciences (SANS), Shanghai, 200241, China.
Xiaoya CaoFengxian Central Hospital Affiliated to Southern Medical University, Shanghai, 201499, China.
Tingyue GongDepartment of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Jialiang SunFengxian Central Hospital Affiliated to Southern Medical University, Shanghai, 201499, China.
Yaqiang HuShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai Academy of Natural Sciences (SANS), Shanghai, 200241, China.
Zhongwei HuFengxian Central Hospital Affiliated to Southern Medical University, Shanghai, 201499, China.
Yuxuan LaiFengxian Central Hospital Affiliated to Southern Medical University, Shanghai, 201499, China.
Dan ZhangShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai Academy of Natural Sciences (SANS), Shanghai, 200241, China.
Neil WarnerSickKids Inflammatory Bowel Disease Center, Research Institute, Hospital for Sick Children, Toronto, M5G 1H3, Canada.
Holm H UhligOxford Biomedical Research Centre, University of Oxford, Oxford, OX3 7BN, UK.
Qi LiSickKids Inflammatory Bowel Disease Center, Research Institute, Hospital for Sick Children, Toronto, M5G 1H3, Canada.
Aleixo M MuiseSickKids Inflammatory Bowel Disease Center, Research Institute, Hospital for Sick Children, Toronto, M5G 1H3, Canada.
Yamin TanDepartment of Hematology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China.
Ying HuangDepartment of Gastroenterology, Pediatric Inflammatory Bowel Disease Research Center, Children's Hospital of Fudan University, Shanghai, 201102, China.
Lianfu DengDepartment of Orthopedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopedics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Liufu DengShanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Zhenliang SunFengxian Central Hospital Affiliated to Southern Medical University, Shanghai, 201499, China.
Ming ZhongDepartment of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. drzhongming1966@163.com.
Xueli ZhangFengxian Central Hospital Affiliated to Southern Medical University, Shanghai, 201499, China. lejing1996@163.com.
Dali LiShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai Academy of Natural Sciences (SANS), Shanghai, 200241, China. dlli@bio.ecnu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSCs) play a crucial role in tumor-associated immune suppression and in impeding immune checkpoint blockade (ICB) therapies; however, effective intervention strategies targeting MDSCs remain limited. In this study, we observed a positive correlation between spleen tyrosine kinase (SYK) activity in immune cells and tumor progression in human cancers. Utilizing a mouse model with a gain-of-function SYK

Indexed as

immunotherapymyeloid-derived suppressor cellspatient-derived organoidsspleen tyrosine kinasetumor microenvironment

Identifiers

PMID42400713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.